Most Read Articles
15 Aug 2017
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
04 Aug 2017
Chronic obstructive pulmonary disease (COPD) is the fourth cause of global mortality, with experts predicting a potential future rise in the prevalence rates of COPD. 
11 May 2016

In conjunction with World Asthma Day which falls on 3rd May 2016, MIMS Doctor speaks to a renowned respiratory medicine specialist, Dato' Dr. Hj Abdul Razak Abdul Muttalif, regarding the chronic airway disease.

Pearl Toh, 22 May 2016
Asthma patients on salmeterol, a long-acting beta-agonist (LABA), plus fluticasone inhaled corticosteroid (ICS) combination therapy did not have a greater risk of serious asthma-related events compared with patients receiving fluticasone alone, according to the recent AUSTRI* study.

Ambrisentan-tadalafil combination provides benefit in pulmonary arterial hypertension

Audrey Abella
18 Sep 2017

First-line combination therapy with ambrisentan plus tadalafil provided clinical benefits for patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), particularly systemic sclerosis-associated PAH (SSc-PAH), according to a post hoc analysis of the AMBITION* trial.

The primary analysis set comprised 500 treatment-naïve patients who had WHO functional class II/III PAH at baseline. A total of 187 patients diagnosed with CTD-PAH, 118 of which were SSc-PAH cases, were randomized to once-daily ambrisentan (10 mg, n=44), tadalafil (40 mg, n=40), or ambrisentan (10 mg) plus tadalafil (40 mg, n=103).

A reduced risk of clinical failure was observed among patients on combination therapy compared with pooled monotherapy, be it patients with CTD-PAH (hazard ratio [HR], 0.43, 95 percent confidence interval [CI], 0.24–0.77) or SSc-PAH (HR, 0.44, 95 percent CI, 0.22–0.89). [Ann Rheum Dis 2017;76:1219-1227]

Compared with pooled monotherapy, combination therapy also resulted in greater mean reduction in NT-proBNP** (CTD-PAH, -60.4 percent vs -43.1 percent and SSc-PAH, -62.8 percent vs -38.4 percent) and increased median 6-minute walking distance (6MWD; CTD-PAH, +42.0 vs +24.3 m and SSc-PAH, +40.9 vs +12.2 m) at week 24.

6MWD could be a useful indicator of treatment response in the SSc-PAH population despite limited improvement with monotherapy, said the researchers.

The most common adverse events associated with combination therapy reported in the CTD-PAH and SSc-PAH groups were peripheral oedema (47 and 45 percent, respectively), headache (33 and 28 percent), and diarrhoea (29 and 28 percent).

Although the study protocol was adjusted to exclude postcapillary pulmonary venous hypertension, [N Engl J Med 2015;373:834-844] evaluation of all randomized subjects receiving the study drug revealed similar results, with risk reductions in both CTD-PAH (HR, 0.48) and SSc-PAH populations (HR, 0.46).

“[E]xcluding patients who failed to meet the revised inclusion criteria had limited impact on the outcome,” said the researchers.

SSc-PAH has a relatively poor prognosis and has been the leading cause of CTD-PAH. [Ann Intern Med 2000;132:425-434; Ann Rheum Dis 2006;65:1336-1340; J Rheumatol 2007;34:2417-2422] The present findings thus provide informative insight on the management of patients with CTD-PAH, noted the researchers.

These results support the notion that CTD-PAH, particularly SSc-PAH, may need a more aggressive treatment regimen to see similar benefits to patients with [idiopathic PAH] … An aggressive approach … with initial combination therapy may improve outcomes and exercise capacity as opposed to treatment with monotherapy,” said the researchers.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
15 Aug 2017
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
04 Aug 2017
Chronic obstructive pulmonary disease (COPD) is the fourth cause of global mortality, with experts predicting a potential future rise in the prevalence rates of COPD. 
11 May 2016

In conjunction with World Asthma Day which falls on 3rd May 2016, MIMS Doctor speaks to a renowned respiratory medicine specialist, Dato' Dr. Hj Abdul Razak Abdul Muttalif, regarding the chronic airway disease.

Pearl Toh, 22 May 2016
Asthma patients on salmeterol, a long-acting beta-agonist (LABA), plus fluticasone inhaled corticosteroid (ICS) combination therapy did not have a greater risk of serious asthma-related events compared with patients receiving fluticasone alone, according to the recent AUSTRI* study.